Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Some exact results for the Ashkin-Teller model
1979
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
2002
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
2001
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
2008
Estrogen receptors and human disease
2006 Standout
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
1995
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
2008
Ovarian cancer
2014 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
1997
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer
2002
Imaging in the era of molecular oncology
2008 StandoutNature
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
2010
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents
2000
Electropotential measurements as a new diagnostic modality for breast cancer
1998
Efficient, Multiple-Range Random Walk Algorithm to Calculate the Density of States
2001 Standout
Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy
2003
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial
1999
New approaches for imaging tumour responses to treatment
2008
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Controlling Cell Behavior Electrically: Current Views and Future Potential
2005 Standout
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
1998 Standout
Anemia of Chronic Disease
2005 Standout
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
Dislocation-mediated melting in two dimensions
1979 Standout
Spin glasses: Experimental facts, theoretical concepts, and open questions
1986 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
2005
Nonuniversal critical behavior and first-order transitions in a coupledXY-Ising model
1991 StandoutNobel
New numerical method to study phase transitions
1990 StandoutNobel
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
Nanoscale Metal–Organic Frameworks for Biomedical Imaging and Drug Delivery
2011 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
2003
Community detection in graphs
2009 Standout
Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer
2002
Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment
2013
Statistical physics of social dynamics
2009 Standout
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Transfer-matrix study of the staggered body-centered solid-on-solid model
1997
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
The 3D Z3 spin model and the deconfinement transition in QCD: A problem of universality
1989 StandoutNobel
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?
2008 Standout
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Phase diagram of the restricted solid-on-solid model coupled to the Ising model
1997 StandoutNobel
Chemotherapy Use among Medicare Beneficiaries at the End of Life
2003
Renormalization-group treatment of a Potts lattice gas for krypton adsorbed onto graphite
1978
Chemisorption geometry of hydrogen on Ni(111): Order and disorder
1979 StandoutNobel
Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
2010
Dynamics of the one-dimensional Potts model
1986 StandoutNobel
Finite-size scaling and Monte Carlo simulations of first-order phase transitions
1991 StandoutNobel
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
2008
The Potts model
1982 Standout
Evolutionary games on graphs
2007 Standout
Superfluidity and phase separation in helium films
1979
Helicity modulus behavior of a frustrated X Y model
1988 StandoutNobel
Scaling and Renormalization in Statistical Physics
1997 StandoutNobel
Spin glass phase in the four-state three-dimensional Potts model
2009 StandoutNobel
Phase transitions in two-dimensional uniformly frustratedXY models. II. General scheme
1986
Classification of Order-Disorder Transitions in Common Adsorbed Systems: Realization of the Four-State Potts Model
1977
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
A relation between the temperature exponents of the eight-vertex and q-state Potts model
1979
Three-dimensionalq-state Potts model: Monte Carlo study nearq=3
1991 StandoutNobel
Works of S.E. Ashley being referenced
Carboplatin (JM8), etoposide (VP16) and thoracic Irradiation for small cell lung cancer (S.C.L.C.): An evaluation of lung toxicity
1988
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome
1993
How many tests are required in the diagnosis of palpable breast abnormalities?
1990
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
1995
A renormalisation group investigation of the Ashkin-Teller-Potts model
1978
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
2000
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
2000
A variational renormalization group approach to two coupled Ising systems
1976